CLRB (Cellectar Biosciences) Marketable Securities: $0.00 Mil (As of Mar. 2026)


CLRB Cellectar Biosciences Inc CLRB
23 GF Score
Price $2.72
! 1 Warning Sign
View Full Analysis

What is Cellectar Biosciences Marketable Securities?

Cellectar Biosciences CLRB -1.42% 23 Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus rates CLRB with a GF Score™ of 23/100. The stock has 1 warning sign investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Cellectar Biosciences's Marketable Securities for the quarter that ended in Mar. 2026 was $0.00 Mil.

Cellectar Biosciences  (NAS:CLRB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Cellectar Biosciences Marketable Securities Related Terms

Cellectar Biosciences Marketable Securities Historical Data

* Premium members only.

The historical data trend for Cellectar Biosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectar Biosciences Marketable Securities Chart

Cellectar Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Cellectar Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CLRB
23GF Score
Cellectar Biosciences Inc CLRB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cellectar Biosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $0.00 Mil mean?
Cellectar Biosciences (CLRB) has a Marketable Securities of $0.00 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cellectar Biosciences and its competitors.
Is Cellectar Biosciences' Marketable Securities too high?
Cellectar Biosciences' current Marketable Securities is $0.00 Mil. Overall, Cellectar Biosciences has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Cellectar Biosciences' Marketable Securities compare to OTLC and PTN?
Cellectar Biosciences' Marketable Securities of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Cellectar Biosciences and its competitors. Cellectar Biosciences's current Marketable Securities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellectar Biosciences stock overvalued right now?
Cellectar Biosciences (CLRB) has a current Marketable Securities of $0.00 Mil. The current Marketable Securities is $0.00 Mil. Cellectar Biosciences' overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Cellectar Biosciences (CLRB), the current Marketable Securities is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cellectar Biosciences Business Description

Address 100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
23GF Score

Get the complete analysis for CLRB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.72
Price